Oral Answers to Questions Debate

Full Debate: Read Full Debate
Department: Northern Ireland Office

Oral Answers to Questions

Richard Bacon Excerpts
Wednesday 5th December 2012

(11 years, 5 months ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Lord Cameron of Chipping Norton Portrait The Prime Minister
- Hansard - - - Excerpts

The right hon. Gentleman is 100% wrong: we are increasing spending on the NHS and we are cutting the deficit. Yes, we have cut the deficit by 25%, there are a million more private sector jobs, businesses are starting up at a higher rate than at any time in our history, this economy is on the right track, we are equipping Britain for the global race and, unlike the Labour party, we are on the side of people who work hard and want to do the right thing. And what is the right hon. Gentleman’s answer? More borrowing, more spending, more of the things that got us into the mess in the first place.

Richard Bacon Portrait Mr Richard Bacon (South Norfolk) (Con)
- Hansard - -

Q3. Three years ago, the NHS spent £500 million on Tamiflu without having seen all the data on effectiveness or safety. Given that, far from that being an isolated case, it is normal for the drugs industry to have almost complete control over the evidence base on which crucial public decisions are made, will the Prime Minister ask Roche to make available the full clinical study reports on Tamiflu, so that doctors, patients and taxpayers are not misled?

Lord Cameron of Chipping Norton Portrait The Prime Minister
- Hansard - - - Excerpts

My hon. Friend does excellent work on behalf of the taxpayer, partly through all the good questions that he asks. He has raised an important issue, involving not only the cost to the taxpayer but the possible overstatement of benefits to patients. There needs to be more transparency in clinical trials data, and we are committed to ensuring that that happens. The European Medicine Agency’s work in this regard is supported, and from next year there will be a legal requirement to publish summary reports from clinical trials.